Cited by 307Lung Cancer Treatments and MutationsHER2/EGFR in Cancer ResearchLung Cancer Diagnosis and Treatment

The DOI matches its Crossref record; 47 of the 48 references it cites were found in a registry or an index.

Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non–Small-Cell Lung Cancer Patients with EGFR Mutations

Open access

Rosell, Rafael, Molina, Miguel Angel, Costa, Carlota, Simonetti, Sara, Gimenez-Capitan, Ana, Bertran-Alamillo, Jordi, Mayo, Clara, Moran, Teresa, Mendez, Pedro, Cardenal, Felipe, Isla, Dolores, Provencio, Mariano, Cobo, Manuel, Insa, Amelia, Garcia-Campelo, Rosario, Reguart, Noemi, Majem, Margarita, Viteri, Santiago, Carcereny, Enric, Porta, Ruth, Massuti, Bartomeu, Queralt, Cristina, de Aguirre, Itziar, Sanchez, Jose Miguel, Sanchez-Ronco, Maria, Mate, Jose Luis, Ariza, Aurelio, Benlloch, Susana, Sanchez, Jose Javier, Bivona, Trever G, Sawyers, Charles L, Taron, Miquel·2011·Clinical Cancer Research

DOI 10.1158/1078-0432.ccr-10-2158

Published version of a preprint

Open this paper in CoChat — free account

Abstract

PURPOSE: Advanced non-small-cell lung cancer (NSCLC) patients harboring epidermal growth factor receptor (EGFR) mutations (deletion in exon 19 or L858R) show an impressive progression-free survival of 14 months when treated with erlotinib. However, the presence of EGFR mutations can only imperfectly predict outcome. We hypothesized that progression-free survival could be influenced both by the pretreatment EGFR T790M mutation and by components of DNA repair pathways. EXPERIMENTAL DESIGN: We assessed the T790M mutation in pretreatment diagnostic specimens from 129 erlotinib-treated advanced NSCLC patients with EGFR mutations. The expression of eight genes and two proteins involved in DNA repair and four receptor tyrosine kinases was also examined. RESULTS: The EGFR T790M mutation was observed in 45 of 129 patients (35%). Progression-free survival was 12 months in patients with and 18 months in patients without the T790M mutation (P = 0.05). Progression-free survival was 27 months in patients with low BRCA1 mRNA levels, 18 months in those with intermediate levels, and 10 months in those with high levels (P = 0.02). In the multivariate analysis, the presence of the T790M mutation (HR, 4.35; P = 0.001), intermediate BRCA1 levels (HR, 8.19; P < 0.0001), and high BRCA1 levels (HR, 8.46; P < 0.0001) emerged as markers of shorter progression-free survival. CONCLUSIONS: Low BRCA1 levels neutralized the negative effect of the T790M mutation and were associated with longer progression-free survival to erlotinib. We advocate baseline assessment of the T790M mutation and BRCA1 expression to predict outcome and provide alternative individualized treatment to patients based on T790M mutations and BRCA1 expression.

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-10-2158

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909530 · Cited by 5,525
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., Seto, T., Satouchi, M., Tada, H., Hirashima, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70364-x · Cited by 4,090
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., Majem, M., Lopez-Vivanco, G., Isla, D., Provencio, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904554 · Cited by 2,373
Self-citation
The DNA Damage Response: Ten Years After
Harper, J. W., & Elledge, S. J. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.11.015 · Cited by 1,705
Detection of Mutations in EGFR in Circulating Lung-Cancer Cells
Maheswaran, S., Sequist, L. V., Nagrath, S., Ulkus, L., Brannigan, B., Collura, C. V., Inserra, E., Diederichs, S., Iafrate, A. J., Bell, D. W., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800668 · Cited by 1,617

Show all 48 references

Sorted by citations

Items 101–200 of 307

Combined FGFR and Akt pathway inhibition abrogates growth of FGFR1 overexpressing EGFR-TKI-resistant NSCLC cells
Terp, M. G., Jacobsen, K., Molina‐Vila, M. Á., Karachaliou, N., Beck, H. C., Bertrán-Alamillo, J., Giménez-Capitán, A. A., Cardona, A. F., Rosell, R., & Ditzel, H. J. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00208-w · Cited by 46
Self-citation
The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR-Mutant Non–Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors
Lee, J. Y., Ku, B. M., Lim, S. H., Lee, M., Kim, H., Kim, M., Kim, S., Jung, H. A., Sun, J., Ahn, J. S., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000535 · Cited by 48
Cancer stem cell biomarkers in egfr-mutation–positive non–small-cell lung cancer
Codony-Servat, J., Codony-Servat, C., Cardona, A. F., Giménez-Capitán, A., Drozdowskyj, A., Berenguer, J., Bracht, J. W. P., Ito, M., Karachaliou, N., & Rosell, R. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2019.02.005 · Cited by 46
Self-citation
Primary and acquired EGFR T790M-mutant NSCLC patients identified by routine mutation testing show different characteristics but may both respond to osimertinib treatment
Li, W., Qiu, T., Guo, L., Ling, Y., Gao, Y., Ying, J., & He, J. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.03.005 · Cited by 47
Effectiveness of tyrosine kinase inhibitors on uncommon E709X epidermal growth factor receptor mutations in non-small-cell lung cancer
Wu, J.-Y., & Shih, J.-Y. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s118071 · Cited by 44
The Role of Irreversible HER Family Inhibition in the Treatment of Patients with Non-Small Cell Lung Cancer
Kwak, E. L. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-0087 · Cited by 44
Most T790M mutations are present on the same EGFR allele as activating mutations in patients with non–small cell lung cancer
Hidaka, N., Iwama, E., Kubo, N., Harada, T., Miyawaki, K., Tanaka, K., Okamoto, I., Baba, E., Akashi, K., Sasaki, H., et al. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.02.019 · Cited by 44
Comparison of cross-platform technologies for EGFR T790M testing in patients with non-small cell lung cancer
Li, X., & Zhou, C. (2017) · Oncotarget · doi:10.18632/oncotarget.19007 · Cited by 43
Successes and Limitations of Targeted Cancer Therapy in Lung Cancer
Suda, K., & Mitsudomi, T. (2014) · Progress in tumor research · doi:10.1159/000355902 · Cited by 43
Exploration of resistance mechanisms for epidermal growth factor receptor‐tyrosine kinase inhibitors based on plasma analysis by digital polymerase chain reaction and next‐generation sequencing
Iwama, E., Sakai, K., Azuma, K., Harada, D., Nosaki, K., Hotta, K., Nishio, M., Kurata, T., Fukuhara, T., Akamatsu, H., et al. (2018) · Cancer Science · doi:10.1111/cas.13820 · Cited by 41
Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL)
García‐Campelo, R., Arrieta, O. G., Massutí, B., Rodríguez‐Abreu, D., Granados, A. L. O., Majem, M., Vicente, D., LIANES, P., Bosch‐Barrera, J., Insa, A., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.09.018 · Cited by 41
Self-citation
Synergy between next generation EGFR tyrosine kinase inhibitors and miR-34a in the inhibition of non-small cell lung cancer
Zhao, J. Y., Guerrero, A., Kelnar, K., Peltier, H. J., & Bader, A. G. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.02.020 · Cited by 41
The predictive role of pretreatment epidermal growth factor receptor T790M mutation on the progression-free survival of tyrosine-kinase inhibitor-treated non-small cell lung cancer patients: a meta-analysis
Lü, S., Ding, D., Yu, Y., Li, Z., & Niu, X. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s58870 · Cited by 41
A systematic profile of clinical inhibitors responsive to EGFR somatic amino acid mutations in lung cancer: implication for the molecular mechanism of drug resistance and sensitivity
Ai, X., Sun, Y., Wang, H., & Lü, S. (2014) · Amino Acids · doi:10.1007/s00726-014-1716-0 · Cited by 40
Non-small cell lung cancer - genetic predictors
Koudeláková, V., Kneblova, M., Trojanec, R., Drábek, J., & Hajdúch, M. (2013) · Biomedical Papers · doi:10.5507/bp.2013.034 · Cited by 39
Tumor heterogeneity: evolution through space and time in EGFR mutant non small cell lung cancer patients.
Majem, M., & Remón, J. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2013.03.09 · Cited by 41
Self-citation
Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy
Ricciuti, B., Baglivo, S., Paglialunga, L., Giglio, A. D., Bellezza, G., Chiari, R., Crinò, L., & Metro, G. (2017) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017702820 · Cited by 39
Ultra-sensitive EGFR T790M Detection as an Independent Prognostic Marker for Lung Cancer Patients Harboring EGFR del19 Mutations and Treated with First-generation TKIs
Vendrell, J. A., Mazières, J., Senal, R., Rouquette, I., Quantin, X., Pujol, J.-L., Roch, B., Bouidioua, A., Godreuil, S., Coyaud, É., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2683 · Cited by 40
Management of hyperglycemia from epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) targeting T790M-mediated resistance.
Villadolid, J. J., Ersek, J. L., Fong, M. K., Sirianno, L., & Story, E. S. (2015) · PubMed Central · doi:10.3978/j.issn.2218-6751.2015.10.01 · Cited by 37
ROR1 as a novel therapeutic target for EGFR-mutant non-small-cell lung cancer patients with the EGFR T790M mutation.
Karachaliou, N., Giménez-Capitán, A. A., Drozdowskyj, A., Viteri, S., Morán, T., Carcereny, E., Massutí, B., Vergnenégre, A., de Marinis, F., Molina‐Vila, M. Á., et al. (2014) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2014.03.02 · Cited by 36
Self-citation
Pharmacogenetics of EGFR in Lung Cancer: Perspectives and Clinical Applications
Mayo, C., Bertrán-Alamillo, J., Molina‐Vila, M. Á., Giménez-Capitán, A. A., Costa, C., & Rosell, R. (2012) · Pharmacogenomics · doi:10.2217/pgs.12.54 · Cited by 36
Self-citation
Targeting the EGFR T790M mutation in non-small-cell lung cancer
Normanno, N., Maiello, M. R., Chicchinelli, N., Iannaccone, A., Esposito, C., Cecio, R. D., D’Alessio, A., & Luca, A. D. (2016) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1272582 · Cited by 37
Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond
Karachaliou, N., Rosell, R., Morales-Espinosa, D., & Viteri, S. (2014) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2014.896210 · Cited by 35
Self-citation
Circulating Tumor Cells and DNA for Real-Time EGFR Detection and Monitoring of Non-Small-Cell Lung Cancer
He, J., Wei, T., & Jing-ping, M. (2017) · Future Oncology · doi:10.2217/fon-2016-0427 · Cited by 36
AZD9291 in EGFR -Mutant Advanced Non-Small-Cell Lung Cancer Patients
Remon, J., & Planchard, D. (2015) · Future Oncology · doi:10.2217/fon.15.250 · Cited by 33
Association of the Expression of Mutant Epidermal Growth Factor Receptor Protein as Determined with Mutation-Specific Antibodies in Non-small Cell Lung Cancer with Progression-Free Survival after Gefitinib Treatment
Azuma, K., Okamoto, I., Kawahara, A., Taira, T., Nakashima, K., Hattori, S., Kinoshita, T., Takeda, M., Nakagawa, K., Takamori, S., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31822eeba2 · Cited by 32
Next-generation sequencing of tyrosine kinase inhibitor-resistant non-small-cell lung cancers in patients harboring epidermal growth factor-activating mutations
Masago, K., Fujita, S., Muraki, M., Hata, A., Okuda, C., Otsuka, K., Kaji, R., Takeshita, J., Kato, R., Katakami, N., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1925-2 · Cited by 33
Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench
Suda, K., Bunn, P. A., Rivard, C. J., Mitsudomi, T., & Hirsch, F. R. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.09.003 · Cited by 33
Highly sensitive and quantitative evaluation of the EGFR T790M mutation by nanofluidic digital PCR
Iwama, E., Takayama, K., Harada, T., Okamoto, I., Ookubo, F., Kishimoto, J., Baba, E., Oda, Y., & Nakanishi, Y. (2015) · Oncotarget · doi:10.18632/oncotarget.4058 · Cited by 32
Should epidermal growth factor receptor tyrosine kinase inhibitors be considered ideal drugs for the treatment of selected advanced non-small cell lung cancer patients?
Rossi, A., Pasquale, R., Esposito, C., & Normanno, N. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.09.001 · Cited by 31
Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation–positive non-small cell lung cancers: an update for recent advances in therapeutics
Chung, C. (2015) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155215577810 · Cited by 31
Estrogen receptors as the novel therapeutic biomarker in non-small cell lung cancer
Kawai, H. (2014) · World Journal of Clinical Oncology · doi:10.5306/wjco.v5.i5.1020 · Cited by 31
Therapeutic approaches for T790M mutation positive non-small-cell lung cancer
Attili, I., Karachaliou, N., Conte, P., Bonanno, L., & Rosell, R. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1508347 · Cited by 32
Self-citation
Strategies for improving outcomes in NSCLC: A look to the future
Stahel, R. A., Peters, S., Baas, P., Brambilla, E. M., Cappuzzo, F., Ruysscher, D. D., Eberhardt, W., Felip, E., Fennell, D. A., Marchetti, A., et al. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.08.025 · Cited by 29
Synergistic anti-tumor effects of a novel phosphatidyl inositol-3 kinase/mammalian target of rapamycin dual inhibitor BGT226 and gefitinib in non-small cell lung cancer cell lines
Katanasaka, Y., Kodera, Y., Yunokawa, M., Kitamura, Y., Tamura, T., & Koizumi, F. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.02.025 · Cited by 29
mRNA expression levels and genetic status of genes involved in the EGFR and NF-κB pathways in metastatic non-small-cell lung cancer patients
Santarpía, M., Magrí, I., Sanchez-Ronco, M., Costa, C., Molina‐Vila, M. Á., Giménez-Capitán, A. A., Bertrán-Alamillo, J., Mayo, C., Benlloch, S., Viteri, S., et al. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-163 · Cited by 28
Self-citation
Survival Outcome Assessed According to Tumor Burden and Progression Patterns in Patients With Epidermal Growth Factor Receptor Mutant Lung Adenocarcinoma Undergoing Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy
Ki, Y., Lee, H. Y., Ahn, M., Choi, Y., Lee, J. H., Park, K., & Lee, K. S. (2014) · Clinical Lung Cancer · doi:10.1016/j.cllc.2014.11.002 · Cited by 29
Role of Genotyping in Non-Small Cell Lung Cancer Treatment
Bonanno, L., Favaretto, A. G., Rugge, M., Tarón, M., & Rosell, R. (2011) · Drugs · doi:10.2165/11597700-000000000-00000 · Cited by 29
Self-citation
Mutational monitoring of EGFR T790M in cfDNA for clinical outcome prediction in EGFR-mutant lung adenocarcinoma
Su, K., Tseng, J., Liao, K.-M., Yang, T., Chen, K., Hsu, K.-H., Yang, P., Yu, S., & Chang, G. (2018) · PLoS ONE · doi:10.1371/journal.pone.0207001 · Cited by 29
Prognostic and predictive biomarkers for targeted therapy in NSCLC: for whom the bell tolls?
Passiglia, F., Bronte, G., Castiglia, M., Listì, A., Calò, V., Toia, F., Cicero, G., Fanale, D., Rizzo, S., Bazan, V., et al. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1071348 · Cited by 29
First-Line Treatment in EGFR Mutant Non-Small Cell Lung Cancer: Is There a Best Option?
Bulbul, A., & Husain, H. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00094 · Cited by 28
Design, synthesis and 3D-QSAR analysis of novel thiopyranopyrimidine derivatives as potential antitumor agents inhibiting A549 and Hela cancer cells
Zhao, B., Zhao, C.-W., Hu, X., Xu, S., Zhou, L., Guo, Y., Yang, Z., Zhu, W., & Zheng, P. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111809 · Cited by 27
Epidermal growth factor receptor tyrosine-kinase inhibitor treatment resistance in non-small cell lung cancer: biological basis and therapeutic strategies
Carrera, S., Buqué, A., Azkona, E., Aresti, U., Calvo, B., Sancho, A., Arruti, M., Nuño, M., Rubio, I., de Lobera, A. R., et al. (2013) · Clinical & Translational Oncology · doi:10.1007/s12094-013-1143-9 · Cited by 26
Rare Mutations in Non-Small-Cell Lung Cancer
D’Arcangelo, M., D’Incecco, A., & Cappuzzo, F. (2013) · Future Oncology · doi:10.2217/fon.13.16 · Cited by 26
EGFR Tyrosine Kinase Inhibitors: Difference in Efficacy and Resistance
Robinson, K. W., & Sandler, A. B. (2013) · Current Oncology Reports · doi:10.1007/s11912-013-0323-7 · Cited by 26
Monitoring Reversal of MET-Mediated Resistance to EGFR Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer Using 3′-Deoxy-3′-[18F]-Fluorothymidine Positron Emission Tomography
Iommelli, F., Rosa, V. D., Gargiulo, S., Panico, M., Monti, M., Greco, A., Gramanzini, M., Ortosecco, G., Fonti, R., Brunetti, A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0264 · Cited by 26
The predictive value of 53BP1 and BRCA1 mRNA expression in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy
Bonanno, L., Costa, C., Majem, M., Sánchez, J. J., Giménez-Capitán, A. A., Rodríguez, I., Vergnenégre, A., Massutí, B., Favaretto, A. G., Rugge, M., et al. (2013) · Oncotarget · doi:10.18632/oncotarget.1157 · Cited by 26
Self-citation
Clinical Implications of the T790M Mutation in Disease Characteristics and Treatment Response in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Non–Small-Cell Lung Cancer (NSCLC)
Gaut, D. L., Sim, M., Yue, Y., Wolf, B. R., Abarca, P. A., Carroll, J., Goldman, J. W., & Garon, E. B. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.06.004 · Cited by 26
Intratumoral distribution of EGFR mutations and copy number in metastatic lung cancer, what impact on the initial molecular diagnosis?
Mansuet‐Lupo, A., Zouiti, F., Alifano, M., Tallet, A., Charpentier, M.-C., Ducruit, V., Devez, F., Lemaitre, F., Laurent‐Puig, P., Damotte, D., et al. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-131 · Cited by 25
Tyrosine kinase inhibitors for non-small-cell lung cancer: finding patients who will be responsive
Santarpía, M., Altavilla, G., Salazar, M., Magrí, I., Pettineo, G., Benecchi, S., & Rosell, R. (2011) · Expert Review of Respiratory Medicine · doi:10.1586/ers.11.27 · Cited by 24
Self-citation
The impact of genomic context on outcomes of solid cancer patients treated with genotype-matched targeted therapies: a comprehensive review
Fulton-Ward, T., & Middleton, G. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.10.124 · Cited by 23
Clinical Predictors of Response to EGFR Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Non-Small Cell Lung Cancer
Fukihara, J., Watanabe, N., Taniguchi, H., Kondoh, Y., Kimura, T., Kataoka, K., Matsuda, T., Yokoyama, T., & Hasegawa, Y. (2014) · Oncology · doi:10.1159/000357129 · Cited by 23
Use of SuperARMS EGFR Mutation Detection Kit to Detect EGFR in Plasma Cell-free DNA of Patients With Lung Adenocarcinoma
Cui, S., Ye, L., Wang, H., Chu, T., Zhao, Y., Gu, A., Xiong, L., Shi, C., & Jiang, L. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.12.009 · Cited by 23
Emerging treatment for advanced lung cancer withEGFRmutation
Inal, C., Yilmaz, E., Piperdi, B., Perez-Soler, R., & Cheng, H. (2015) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2015.1058778 · Cited by 23
A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib
Morán, T., Palmero, R., Provencio, M., Insa, A., Majem, M., Reguart, N., Bosch‐Barrera, J., Isla, D., Carcereny, E., Lee, C., et al. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.03.009 · Cited by 23
Self-citation
Beyond EGFR TKI in EGFR-mutant Non-Small Cell Lung Cancer patients: Main challenges still to be overcome
Remón, J., Morán, T., Reguart, N., Majem, M., Carcereny, E., & LIANES, P. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.03.006 · Cited by 22
Self-citation
Effect of DNA Repair Deficiencies on the Cytotoxicity of Drugs Used in Cancer Therapy - A Review
Calderón‐Montaño, J. M., Burgos‐Morón, E., Orta, M. L., & López‐Lázaro, M. (2014) · Current Medicinal Chemistry · doi:10.2174/0929867321666140601203816 · Cited by 22
Highly sensitive and noninvasive detection of epidermal growth factor receptor T790M mutation in non-small cell lung cancer
He, C., Zheng, L., Xu, Y., Liu, M., Li, Y., & Xu, J. (2013) · Clinica Chimica Acta · doi:10.1016/j.cca.2013.07.012 · Cited by 22
BID expression determines the apoptotic fate of cancer cells after abrogation of the spindle assembly checkpoint by AURKB or TTK inhibitors
Bertrán-Alamillo, J., Giménez-Capitán, A. A., Roman, R. A., Talbot, S., Whiteley, R., Floc’h, N., Martínez‐Pérez, E., Martin, M. J., Smith, P. D., Sullivan, I., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01815-w · Cited by 21
Self-citation
The distinctive nature of adenocarcinoma of the lung
Roviello, G. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s89225 · Cited by 22
A peptide antigen derived from EGFR T790M is immunogenic in non-small cell lung cancer
Ofuji, K., Tada, Y., Yoshikawa, T., Shimomura, M., Yoshimura, M., Saito, K., Nakamoto, Y., & Nakatsura, T. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2787 · Cited by 20
Micropapillary: A component more likely to harbour heterogeneous EGFR mutations in lung adenocarcinomas
Cai, Y., Dong, Y., Wu, H., Liu, Z.-C., Zhou, L.-J., Su, D., Chen, X.-J., Zhang, L., & Zhao, Y. (2016) · Scientific Reports · doi:10.1038/srep23755 · Cited by 20
Inference for High-Dimensional Censored Quantile Regression
Fei, Z., Zheng, Q., Hong, H. G., & Li, Y. (2021) · Journal of the American Statistical Association · doi:10.1080/01621459.2021.1957900 · Cited by 19
BRCA1, LMO4, and CtIP mRNA Expression in Erlotinib-Treated Non–Small-Cell Lung Cancer Patients with EGFR Mutations
Karachaliou, N., Costa, C., Giménez-Capitán, A. A., Molina‐Vila, M. Á., Bertrán-Alamillo, J., Mayo, C., Massutí, B., Majem, M., Carcereny, E., Morán, T., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31827db621 · Cited by 19
Self-citation
Activity of Gefitinib in a Non–Small-Cell Lung Cancer Patient with Both Activating and Resistance EGFR Mutations
Morabito, A., Costanzo, R., Rachiglio, A. M., Pasquale, R., Sandomenico, C., Franco, R., Montanino, A., Lutio, E. D., Rocco, G., & Normanno, N. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318286cc26 · Cited by 19
Structure-based inhibitory peptide design targeting peptide-substrate binding site in EGFR tyrosine kinase
Tavakoli, F., & Ganjalikhany, M. R. (2019) · PLoS ONE · doi:10.1371/journal.pone.0217031 · Cited by 19
Four generations of EGFR TKIs associated with different pathogenic mutations in non-small cell lung carcinoma
Li, R., Zhou, X., Yao, H.-J., & Li, L. (2020) · Journal of drug targeting · doi:10.1080/1061186x.2020.1737934 · Cited by 19
Presence of the minor EGFR T790M mutation is associated with drug-sensitive EGFR mutations in lung adenocarcinoma patients
Hashida, S., Soh, J., Toyooka, S., Tanaka, T., Furukawa, M., Shien, K., Yamamoto, H., Asano, H., Tsukuda, K., Hagiwara, K., et al. (2014) · Oncology Reports · doi:10.3892/or.2014.3197 · Cited by 19
Staurosporine scaffold–based rational discovery of the wild‐type sparing reversible inhibitors of EGFR T790M gatekeeper mutant in lung cancer with analog‐sensitive kinase technology
Song, X., Liu, X., & Ding, X. (2016) · Journal of Molecular Recognition · doi:10.1002/jmr.2590 · Cited by 19
A sensitive and practical method to detect the T790M mutation in the epidermal growth factor receptor
Zhao, J., FENG, H.-H., Zhao, J., LIU, L.-C., Xie, F., Xu, Y., CHEN, M.-J., Zhong, W., Longyun, L. I., WANG, H.-P., et al. (2016) · Oncology Letters · doi:10.3892/ol.2016.4263 · Cited by 18
Multiplex Ultrasensitive Genotyping of Patients with Non-Small Cell Lung Cancer for Epidermal Growth Factor Receptor (EGFR) Mutations by Means of Picodroplet Digital PCR
Watanabe, M., Kawaguchi, T., Isa, S., Ando, M., Tamiya, A., Kubo, A., Saka, H., Takeo, S., Adachi, H., Tagawa, T., et al. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.06.003 · Cited by 18
Reducing Artifactual EGFR T790M Mutations in DNA from Formalin-Fixed Paraffin-Embedded Tissue by Use of Thymine-DNA Glycosylase
Do, H., Molania, R., Mitchell, P. L., Vaiškunaite, R., Murdoch, J. D., & Dobrovic, A. (2017) · Clinical Chemistry · doi:10.1373/clinchem.2017.271932 · Cited by 17
Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial
Molina‐Vila, M. Á., Stahel, R. A., Dafni, U. G., Jordana‐Ariza, N., Balada‐Bel, A., Garzón‐Ibáñez, M., García‐Peláez, B., Mayo‐de‐las‐Casas, C., Felip, E., Fontecedro, A. C., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.11.023 · Cited by 18
Self-citation
Detection of EGFR Mutations in Plasma Cell-Free Tumor DNA of TKI-Treated Advanced-NSCLC Patients by Three Methodologies: Scorpion-ARMS, PNAClamp, and Digital PCR
Siggillino, A., Ulivi, P., Pasini, L., Reda, M. S., Chiadini, E., Tofanetti, F. R., Baglivo, S., Metro, G., Crinò, L., Delmonte, A., et al. (2020) · Diagnostics · doi:10.3390/diagnostics10121062 · Cited by 18
Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical Implications
Quintanal-Villalonga, À., Paz-Ares, L. G., Ferrer, I., & Molina‐Pinelo, S. (2016) · Disease Markers · doi:10.1155/2016/9214056 · Cited by 16
Coexistence of sensitive and resistant epidermal growth factor receptor (EGFR) mutations in pretreatment non-small cell lung cancer (NSCLC) patients: First or third generation tyrosine kinase inhibitors (TKIs)?
Zhang, B., Xu, J., Zhang, X., Gu, P., Wang, H., Wang, S., Qian, J., Qiao, R., Zhang, Y., Yang, W., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.01.006 · Cited by 17
The detectability of the pretreatment EGFR T790M mutations in lung adenocarcinoma using CAST-PCR and digital PCR
Tatematsu, T., Okuda, K., Suzuki, A., Oda, R., Sakane, T., Kawano, O., Haneda, H., Moriyama, S., Sasaki, H., & Nakanishi, R. (2017) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.07.02 · Cited by 16
EGFR T790M Mutation in TKI-Naïve Clinical Samples: Frequency, Tissue Mosaicism, Predictive Value and Awareness on Artifacts
Lavdovskaia, E. D., Iyevleva, A. G., Соколенко, А. П., Mitiushkina, N. V., Преображенская, Е. В., Tiurin, V. I., Ivantsov, A. O., Валерьевич, Б. И., Stelmakh, L. V., Moiseenko, F. V., et al. (2018) · Oncology Research and Treatment · doi:10.1159/000491441 · Cited by 17
ALDOC promotes non-small cell lung cancer through affecting MYC-mediated UBE2N transcription and regulating Wnt/β-catenin pathway
Shang, B., Lu, F., Jiang, S., Xing, M., Mao, X., Yang, G., & Zhang, H. (2023) · Aging · doi:10.18632/aging.205038 · Cited by 15
A Patient With Metastatic Lung Adenocarcinoma Harboring ConcurrentEGFRL858R,EGFRGermline T790M, andPIK3CAMutations: The Challenge of Interpreting Results of Comprehensive Mutational Testing in Lung Cancer
Lammers, P. E., Lovly, C. M., & Horn, L. (2014) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2014.0002 · Cited by 15
Mutation Profile of ResectedEGFR-Mutated Lung Adenocarcinoma by Next-Generation Sequencing
Zhao, Z.-R., Lin, Y., Ng, C. S. H., Zhang, R., Wu, X., Ou, Q., Chen, W., Zhou, W., Lin, Y., Su, X., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0567 · Cited by 16
Different Clinicopathologic and Computed Tomography Imaging Characteristics of Primary and Acquired EGFR T790M Mutations in Patients with Non-Small-Cell Lung Cancer
Hou, D., Li, W., Wang, S., Huang, Y., Wang, J., Tang, W., Zhou, L., Qi, L., Wu, N., & Zhao, S. (2021) · Cancer Management and Research · doi:10.2147/cmar.s323972 · Cited by 15
Combined therapy with epidermal growth factor receptor tyrosine kinase inhibitors for non–small cell lung cancer
Iwama, E., Nakanishi, Y., & Okamoto, I. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1432356 · Cited by 15
Association of PALB2 Messenger RNA Expression with Platinum-Docetaxel Efficacy in Advanced Non–Small Cell Lung Cancer
Karachaliou, N., Bracht, J. W. P., Bruno, M. F., Drozdowskyj, A., Giménez-Capitán, A. A., Morán, T., Carcereny, E., Cobo, M., Dómine, M., CHAIB-OUKADOUR, I., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.10.168 · Cited by 15
Self-citation
NCCN Guidelines Version 1.2015 Panel Members Non-Small Cell Lung Cancer
Ettinger, D. S., Kimmel, S., Wood, D. E., Akerley, W., Bazhenova, L. A., Borghaei, H., Camidge, D. R., Cheney, R. T., Chirieac, L. R., Jahan, T. M., et al. (2014) · Cited by 14
Downregulating oncogenic receptor: From bench to clinic
Zhu, G., Saboor-Yaraghi, A. A., Yarden, Y., Santos, J., & Jc, N. (2016) · Hematology & Medical Oncology · doi:10.15761/hmo.1000106 · Cited by 14
Detection of EGFR and BRAF mutations by competitive allele-specific TaqMan polymerase chain reaction in lung adenocarcinoma
Yang, Y., Meng, Y., Zhang, H., Shen, X., Li, R., Yu, L., Liu, B., & Wang, L. (2017) · Oncology Letters · doi:10.3892/ol.2017.7652 · Cited by 15
Utility of different massive parallel sequencing platforms for mutation profiling in clinical samples and identification of pitfalls using FFPE tissue
Fassunke, J., Haller, F., Hebele, S., Moskalev, E. A., Penzel, R., Pfarr, N., Merkelbach‐Bruse, S., & Endris, V. (2015) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2015.2339 · Cited by 13
Predictive impact of low-frequency pretreatment T790M mutation in patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors
Matsumoto, Y., Sawa, K., Fukui, M., Oyanagi, J., Yoshimoto, N., Suzumura, T., Watanabe, T., Kaneda, H., Mitsuoka, S., Asai, K., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.10.029 · Cited by 13
Molecular and Histological Changes in Post-Treatment Biopsies of Non-Squamous Non-Small Cell Lung Cancer: A Retrospective Study
Vatrano, S., Righi, L., Vavalà, T., Rapa, I., Busso, M., Izzo, S., Cappia, S., Veltri, A., Papotti, M., Scagliotti, G. V., et al. (2015) · Targeted Oncology · doi:10.1007/s11523-015-0383-8 · Cited by 14
Phase II trial of erlotinib in patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations: additive analysis of pharmacokinetics
Motoshima, K., Nakamura, Y., Sano, K., Ikegami, Y., Ikeda, T., Mizoguchi, K., Takemoto, S., Fukuda, M., Nagashima, S., Iida, T., et al. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2307-6 · Cited by 13
EGFR CA repeat polymorphism predict clinical outcome in EGFR mutation positive NSCLC patients treated with erlotinib
Winther‐Larsen, A., Nissen, P. H., Meldgaard, P., Weber, B., & Sørensen, B. S. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.06.016 · Cited by 13
Advanced non-small-cell lung cancer with epidermal growth factor receptor mutations: current evidence and future perspectives
Costanzo, R., Montanino, A., Maïo, M. D., Piccirillo, M. C., Sandomenico, C., Giordano, P., Daniele, G., Franco, R., Perrone, F., Rocco, G., et al. (2013) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2013.845092 · Cited by 12
Clinical management of epidermal growth factor receptor mutation-positive non-small cell lung cancer patients after progression on previous epidermal growth factor receptor tyrosine kinase inhibitors: the necessity of repeated molecular analysis
González-Larriba, J. L., Lázaro-Quintela, M., Cobo, M., Dómine, M., Majem, M., & García‐Campelo, R. (2017) · Translational Lung Cancer Research · doi:10.21037/tlcr.2017.10.03 · Cited by 12
Self-citation
Characterising acquired resistance to erlotinib in non-small cell lung cancer patients
Karachaliou, N., Codony‐Servat, J., Bracht, J. W. P., Ito, M., Filipska, M., Pedraz‐Valdunciel, C., CHAIB-OUKADOUR, I., Bertrán-Alamillo, J., Cardona, A. F., Molina‐Vila, M. Á., et al. (2019) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2019.1656068 · Cited by 13
Self-citation
Lung Adenocarcinoma with Pulmonary Miliary Metastases and Complex Somatic Heterozygous EGFR Mutation
Schaller, A., Beau‐Faller, M., Mennecier, B., Renaud-Picard, B., Weingertner, N., Massard, G., & Quoix, É. (2014) · Case Reports in Oncology · doi:10.1159/000369526 · Cited by 12
Plasma EGFR mutation abundance affects clinical response to first-line EGFR-TKIs in patients with advanced non-small cell lung cancer
Wang, X., Liu, Y., Meng, Z., Wu, Y., Wang, S., Jin, G., Qin, Y., Wang, F., Wang, J., Zhou, H., et al. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-7155 · Cited by 11
Treatment pattern and outcomes in de novo T790M-mutated non-small cell lung cancer
Panda, G. S., Noronha, V., Shah, D., John, G., Chougule, A., Patil, V., Kumar, R., Menon, N. S., Singh, A. K., Chandrani, P., et al. (2022) · ecancermedicalscience · doi:10.3332/ecancer.2022.1385 · Cited by 12
The surgical resection of the primary tumor increases survival in patients with EGFR-mutant advanced non-small cell lung cancer: a tertiary center cohort study
Chen, Y., Su, P., Huang, W., Chang, C., Yen, Y., Lin, C., & Tseng, Y. (2022) · Scientific Reports · doi:10.1038/s41598-022-22957-9 · Cited by 12
The Importance of Molecular Profiling in Predicting Response to Epidermal Growth Factor Receptor Family Inhibitors in Non–Small-Cell Lung Cancer: Focus on Clinical Trial Results
Tsao, A. S., & Papadimitrakopoulou, V. A. (2013) · Clinical Lung Cancer · doi:10.1016/j.cllc.2013.01.001 · Cited by 11

Outcome to erlotinib in non-small cell lung cancer (NSCLC) patients (p) according to the presence of the EGFR T790M mutation and BRCA1 mRNA expression levels in pretreatment biopsies.
Rosell, R., Molina, M. A., Costa, C., Tarón, M., Bertrán-Alamillo, J., Mayo, C., Benlloch, S., Morán, T., Cardenal, F., & Porta, R. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.7514 · Cited by 14
Self-citation
BRCA1, LMO4, and CtIP mRNA Expression in Erlotinib-Treated Non–Small-Cell Lung Cancer Patients with EGFR Mutations
Karachaliou, N., Costa, C., Giménez-Capitán, A. A., Molina‐Vila, M. Á., Bertrán-Alamillo, J., Mayo, C., Massutí, B., Majem, M., Carcereny, E., Morán, T., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31827db621 · Cited by 19
Self-citation
The Impact of EGFR T790M Mutations and BIM mRNA Expression on Outcome in Patients with EGFR -Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial
Costa, C., Molina, M. A., Drozdowskyj, A., Giménez-Capitán, A., Bertran-Alamillo, J., Karachaliou, N., Gervais, R., Massuti, B., Wei, J., Moran, T., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2233 · Cited by 229
Self-citation
Abstract 1727: Correlation between BRCA1 and LMO4 mRNA expression levels in Erlotinib-treated non small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations
Costa, C., Giménez-Capitán, A. A., Benlloch, S., Tarón, M., Jimeno, J. M., Viteri, S., Gascó, A., Camps, C., Carcereny, E., Massutí, B., et al. (2012) · Cancer Research · doi:10.1158/1538-7445.am2012-1727
Self-citation
Abstract 4112: De novo EGFR T790M mutation modifies outcome to second-line erlotinib in non-small cell lung cancer (NSCLC) according to metastatic site and upfront chemotherapy
Rosell, R., Molina‐Vila, M. Á., Sánchez, J. J., Tarón, M., Benlloch, S., Morán, T., Carcereny, E., Cardenal, F., Massutí, B., & Magrí, I. (2011) · Cancer Research · doi:10.1158/1538-7445.am2011-4112 · Cited by 1
Self-citation

See all

Authors: Rosell, R., Molina, M. A., Costa, C., Simonetti, S., Gimenez-Capitan, A., Bertran-Alamillo, J., Mayo, C., Moran, T., Mendez, P., Cardenal, F., Isla, D., Provencio, M., Cobo, M., Insa, A., Garcia-Campelo, R., Reguart, N., Majem, M., Viteri, S., Carcereny, E., Porta, R., Massuti, B., Queralt, C., de Aguirre, I., Sanchez, J. M., Sanchez-Ronco, M., Mate, J. L., Ariza, A., Benlloch, S., Sanchez, J. J., Bivona, T. G., Sawyers, C. L., & Taron, M.
Affiliations: Memorial Sloan Kettering Cancer Center (US)
Authors' Affiliations: 1Catalan Institute of Oncology, Hospital Germans Trias i Pujol; 2Hospital Germans Trias i Pujol, Badalona, Spain; 3USP Dexeus University Institute, Pangaea Biotech; 4Hospital Clinic; and 5Hospital Sant Pau, Barcelona, Spain; 6Catalan Institute of Oncology, Hospital Duran i Reynals, Bellvitge, Spain; 7Hospital Lozano Blesa, Zaragoza, Spain; 8Hospital Puerta de Hierro; 9MD Anderson; and 10Autonomous University of Madrid, Madrid, Spain; 11Hospital Carlos Haya, Malaga, Spain; 12Hospital Clinico Universitario, Valencia, Spain; 13Hospital Juan Canalejo, La Coruña, Spain; 14Catalan Institute of Oncology, Hospital Josep Trueta, Girona, Spain; 15Hospital General, Alicante, Spain; 16University of Alcala de Henares, Alcala de Henares, Spain; 17Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, New York; and 18Howard Hughes Medical Institute, Chevy Chase, Maryland
Corresponding author: Rosell, Rafael
ORCID: Rosell, Rafael
Simonetti, Sara
Isla, Dolores
Provencio, Mariano
Cobo, Manuel
Insa, Amelia
Majem, Margarita
Viteri, Santiago
Carcereny, Enric
Queralt, Cristina
Bivona, Trever G
Sawyers, Charles L
Venue: Clinical Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2011-03-01
Volume: 17
Issue: 5
Pages: 1160-1168
ISSN: 1078-0432 (ISSN-L)
1557-3265
DOI: 10.1158/1078-0432.ccr-10-2158
OpenAlex: W2156560090
Cited by: 304
References: 48
Citations by year: 2026: 2 · 2025: 3 · 2023: 7 · 2022: 9 · 2021: 10 · 2020: 11 · 2019: 20 · 2018: 20 · 2017: 34 · 2016: 31 · 2015: 33 · 2014: 37 · 2013: 47 · 2012: 23
FWCI: 33.19
Type: journal article
Language: en
Open access: green
hdl.handle.net
Licence: other-oa
Locations: Clinical Cancer Research (publishedVersion)
PubMed (publishedVersion)
RUNA. Repositorio Institucional del Sergas (Servicio Gallego de Salud (SERGAS)) (submittedVersion, other-oa)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Keywords: T790M mutation, BRCA1 mRNA expression, erlotinib, advanced non-small cell lung cancer, EGFR mutation, exon 19 deletion, L858R mutation, progression-free survival, DNA repair pathways, predictive biomarkers, personalized treatment
MeSH terms: Erlotinib Hydrochloride, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, DNA Repair, Female, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Quinazolines, RNA, Messenger, Biomarkers, Tumor, Gene Expression, Treatment Outcome, Disease-Free Survival, Genes, erbB-1, BRCA1 Protein, Genes, BRCA1, Receptor Protein-Tyrosine Kinases, Protein Kinase Inhibitors, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non–Small-Cell Lung Cancer Patients with EGFR Mutations

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks